CLINICAL ASPECTS OF CANCER TREATMENT AND NEW BIOCHEMICAL MECHANISMS OF THE DRUG UKRAIN

UGLYANITSA K.M.,¹ NEFYODOV L.I.,² KARAYEDOVA L.M.,² NOWICKY J.W.,³ BRZOSKO W.⁴

1) Oncology Department of Grodno Higher Medical School, Grodno, Belarus.
2) Institute of Biochemistry, National Academy of Sciences of Belarus, Grodno, Belarus.
3) Ukrainian Anti-Cancer Institute, Vienna, Austria.
4) R. Brzosko Memorial Centre of Natural Medicine, Warsaw, Poland.

Address for correspondence: Nefyodov, L.I., Institute of Biochemistry, National Academy of Sciences of Belarus, 50 BLK, Grodno 230017, Belarus.

Summary: A random group of 50 patients in tumor stages T1-3N0-2M0 was selected from breast cancer patients and given Ukrain therapy by intravenous injection. Twenty-five patients received a total dose of 50 mg Ukrain (5 mg every second day, 10 injections altogether). Twenty-five patients received a total dose of 100 mg Ukrain (10 mg every second day, 10 injections altogether).